The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Daniel Sang, MD, a pediatric oncologist at the Children’s Hospital of Philadelphia, and Chiara Bona, MD, a pediatric oncologist at Dana-Farber Boston Children’s Cancer and Blood Disorders Center, discuss their research on financial toxicity in pediatric leukemia.
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a complete response rate of 44 percent. A global phase 3 trial is currently recruiting patients to serve as a confirmatory study for the indication.
The future of registries in the UK came into focus during an afternoon session at SOHO UK with Priyanka Mehta, MBBS, MD, FRCP, FRCPath, a
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
In five years, we hope to have a national system for prescreening to determine eligibility for experimental cancer medicine, allowing the UK to give patients access to trials faster than anywhere else in the world.
To access the SOHO Career Center click the following link.
